All News

Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.

Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.

Pennsylvania has become the center of the outbreak as cases exceed 775 alongside conflicting mortality reports.

The LATA trial found long-acting cabotegravir–rilpivirine is better than daily oral therapy at keeping adolescents virologically suppressed.

The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.

Mark Garofoli, PharmD, BCGP, CPE, CTTS, explains how to guide patients past crowded combination products, uncertain decongestants, and hidden risks in OTC aisles.

Chad Worz, PharmD, BCGP, FASCP, explains why the Main Street Pharmacy Access Act's reimbursement provisions are key to unlocking pharmacy's clinical future.

Cohort studies found no clear cardiovascular benefit from PPV23 vaccination, leaving its role in cardiovascular prevention unresolved.

A high-dose flu vaccine lowered flu- and pneumonia-related hospital stays in patients with chronic lung disease, reinforcing flu and pneumococcal vaccinations.

A guide built from conversations with pharmacists on social media and independent pharmacy owners.

Exploring the effects of weight-loss and GLP-1 therapies, researchers determine the specific metabolic determinants that lead to patients’ weight reduction.

Observed by APhA and ASHP since 2023, bipartisan support has garnered to give pharmacy workforce suicide awareness its own federally recognized day.

Atogepant reduced migraine days during the perimenstrual period, positioning the medication as a potential first treatment option for the condition.

Chad Worz, PharmD, BCGP, FASCP, discusses the Main Street Pharmacy Access Act, a revolutionary pharmacy-focused bill moving through Congress.

Data show that commercially and Medicaid-insured children with chronic or immunocompromising conditions incur 2- to 3-fold higher costs.

Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.

Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.

Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.

Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.

James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.

ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.

As pouched products increase in popularity, researchers assess their pharmacology, harm-reduction potential, and initiation risk.

The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.

Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.

Madeline Sutton, MD, MPH, FACOG, joins to discuss risks of HPV infection among women and how pharmacists can improve outcomes in this area.